These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21506982)

  • 21. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
    Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study.
    Ray P; Hayward J; Michelson D; Lewis E; Schwalbe J; Black S; Shinefield H; Marcy M; Huff K; Ward J; Mullooly J; Chen R; Davis R;
    Pediatr Infect Dis J; 2006 Sep; 25(9):768-73. PubMed ID: 16940831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety concerns regarding combination vaccines: the experience in Japan.
    Andreae MC; Freed GL; Katz SL
    Vaccine; 2004 Sep; 22(29-30):3911-6. PubMed ID: 15364439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of the Australian Childhood Immunisation Register for vaccine safety data linkage.
    Gold M; Dugdale S; Woodman RJ; McCaul KA
    Vaccine; 2010 Jun; 28(26):4308-11. PubMed ID: 20430123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced rate of side effects associated with separate administration of MMR and DTaP-Hib-IPV vaccinations.
    Shneyer E; Strulov A; Rosenfeld Y
    Isr Med Assoc J; 2009 Dec; 11(12):735-8. PubMed ID: 20166340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
    Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
    Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine.
    Barlow WE; Davis RL; Glasser JW; Rhodes PH; Thompson RS; Mullooly JP; Black SB; Shinefield HR; Ward JI; Marcy SM; DeStefano F; Chen RT; Immanuel V; Pearson JA; Vadheim CM; Rebolledo V; Christakis D; Benson PJ; Lewis N;
    N Engl J Med; 2001 Aug; 345(9):656-61. PubMed ID: 11547719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines.
    Deforest A; Long SS; Lischner HW; Girone JA; Clark JL; Srinivasan R; Maguire TG; Diamond SA; Schiller RP; Rothstein EP
    Pediatrics; 1988 Feb; 81(2):237-46. PubMed ID: 3340474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
    Alfredsson R; Svensson E; Trollfors B; Borres MP
    Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.
    Robbins JB; Schneerson R; Trollfors B; Sato H; Sato Y; Rappuoli R; Keith JM
    J Infect Dis; 2005 Jan; 191(1):81-8. PubMed ID: 15593007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined vaccination by measles and hepatitis B vaccines: a new cause of Gianotti-Crosti syndrome.
    Andiran N; Sentürk GB; Bükülmez G
    Dermatology; 2002; 204(1):75-6. PubMed ID: 11834856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunisation with aluminium-containing vaccine of a child with itching nodule following previous vaccination.
    Frederiksen MS; Tofte H
    Vaccine; 2004 Nov; 23(1):1-2. PubMed ID: 15519700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality control of diphtheria tetanus acellular pertussis combined (DTaP) vaccines in Japan.
    Horiuchi Y; Takahashi M; Konda T; Ochiai M; Yamamoto A; Kataoka M; Toyoizumi H; Arakawa Y
    Jpn J Infect Dis; 2001 Oct; 54(5):167-80. PubMed ID: 11754154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.